Hartmann A M, Rujescu D, Giannakouros T, Nikolakaki E, Goedert M, Mandelkow E M, Gao Q S, Andreadis A, Stamm S
Max Planck Institute of Neurobiology, Am Klopferspitz 18a, Martinsried, D-82152, Germany.
Mol Cell Neurosci. 2001 Jul;18(1):80-90. doi: 10.1006/mcne.2001.1000.
Tau is a microtubule-associated protein whose transcript undergoes regulated splicing in the mammalian nervous system. Exon 10 of the gene is an alternatively spliced cassette that is adult-specific and encodes a microtubule-binding domain. Mutations increasing the inclusion of exon 10 result in the production of tau protein which predominantly contains four microtubule-binding repeats and were shown to cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Here we show that exon 10 usage is regulated by CDC2-like kinases CLK1, 2, 3, and 4 that phosphorylate serine-arginine-rich proteins, which in turn regulate pre-mRNA splicing. Cotransfection experiments suggest that CLKs achieve this effect by releasing specific proteins from nuclear storage sites. Our results show that changing pre-mRNA-processing pathways through phosphorylation could be a new therapeutic concept for tauopathies.
Tau是一种与微管相关的蛋白质,其转录本在哺乳动物神经系统中经历受调控的剪接。该基因的外显子10是一个可变剪接的盒式结构,具有成人特异性,编码一个微管结合结构域。增加外显子10包含率的突变会导致tau蛋白的产生,该蛋白主要包含四个微管结合重复序列,并且已被证明会导致与17号染色体相关的额颞叶痴呆和帕金森综合征(FTDP-17)。我们在此表明,外显子10的使用受CDC2样激酶CLK1、2、3和4的调控,这些激酶使富含丝氨酸-精氨酸的蛋白质磷酸化,进而调节前体mRNA剪接。共转染实验表明,CLKs通过从核储存位点释放特定蛋白质来实现这一效应。我们的结果表明,通过磷酸化改变前体mRNA加工途径可能是治疗tau蛋白病的一个新的治疗理念。